Author name: Pharmsky Team

Process-related impurities originating from oil refinement The Problem 2- and 3-monochloropropanediol esters (2-MCPDE and 3-MCPDE) and glycidyl esters (GE) are impurities that form at high temperatures during the oil refining…

NITROSAMINES IN PHARMACEUTICALS Nitrosamine impurities are potential mutagenic carcinogens that present a major safety concern even at trace amounts. Several

PharmSky Research was contracted by a client to manufacture Phase 1 clinical material of a novel, fatty acid based topical

Exciting news!  Thrilled to share that PharmSky Research have officially received the Therapeutic Goods Administration License. A testament to our commitment to quality and

We’re excited to announce that Sameer Agarwal was recently appointed as a Member of PharmSky’s Board of Directors. Sameer brings

PharmSky was challenged to detect the three impurities down to trace levels (ppb) for a client interested in the development

PharmSky was challenged to develop an Analytical Method for a client to characterise a small, polar molecule with poor UV

We’re honored to announce PharmSky’s Chief Scientific Consultant Ben Boyd has been elevated by American Association of Pharmaceutical Scientists (AAPS) to Fellow Status.  Class of 2023

June 5 – 8 Boston, MA The BIO International Convention attracts 15,000+ biotechnology and pharma leaders for one week of

Author: Professor Ben Boyd PharmSky have worked with a client to produce a first-in-class oral liquid emulsion high dose MCT